Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05778617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ambroxol to Slow Progression in Parkinson Disease

Study acronym: ASPro-PD
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Primary completion date: Mar 2027 to Feb 2029
    • Study completion date: Sep 2028 to Sep 2029
    • Start date changed from estimate of Feb 1, 2025 to Feb 25, 2025
    • Site details revised at 15 of 15 sites
  2. Start date: Oct 2024 to Feb 1, 2025v5
  3. Start date: Sep 2023 to Oct 2024
    • Study sites: 4 to 15
    • Eligibility criteria expanded, about 31 words
    v4
  4. Eligibility criteria shortened, about 127 words
    • Secondary endpoints: 39 to 43
    v3
  5. Study sites: 0 to 4v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.
Trial Details
NCT Number NCT05778617
Lead Sponsor University College, London
Conditions
(from sponsor)		 Parkinson Disease
Related terms Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinson Disease, Parkinsonian Disorders, Synucleinopathies
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov